GSK extends Genelabs acquisition deadline
This article was originally published in Scrip
GlaxoSmithKline has extended its $57 million offer to buy the outstanding stock of Genelabs Technologies to comply with the terms of its tender offer. The UK company and its wholly owned subsidiaries must own at least 90% of the total outstanding Genelabs shares on a fully diluted basis. GSK had validly tendered 79.1% of Genelab stock by midnight, New York City time, on December 12th, the original expiry date for the offer. It has received notices of guaranteed delivery of around 1.4 million shares, increasing its stake and that of itswholly owned subsidiaries of Genelabs to 82.5%. The tender offer started on November 12th, after GSK announced the deal at the end of October to strengthen its hepatitis C virus portfolio (Scrip Online, October 30th, 2008). The offer will expire at 5pm, New York City time, on December 29th.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.